Log in

NX1 Nexalis Therapeutics Limited ASX · Australia

Nexalis Therapeutics (NX1) news

Nexalis Therapeutics Limited is a public biotech or pharmaceutical company listed on ASX under the ticker NX1, recorded under Australia. The directory classifies it as Clinical-stage biopharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Nexalis Therapeutics news

We have not published a story on Nexalis Therapeutics yet. When there is news, it will appear here.

Questions about Nexalis Therapeutics

What is the ticker symbol of Nexalis Therapeutics?

Nexalis Therapeutics Limited trades under the ticker NX1 on ASX.

Where is Nexalis Therapeutics listed?

Nexalis Therapeutics Limited is listed on ASX.

Which country or territory is Nexalis Therapeutics listed under?

Our directory records Nexalis Therapeutics Limited under Australia.

What does Nexalis Therapeutics do?

Our directory classifies Nexalis Therapeutics Limited as: Clinical-stage biopharmaceuticals. This is a directory classification, not a description of the pipeline.

What is the ISIN of Nexalis Therapeutics?

The ISIN recorded for Nexalis Therapeutics Limited is AU0000456733.

Does aibio.space cover Nexalis Therapeutics?

aibio.space lists Nexalis Therapeutics Limited among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Nexalis Therapeutics?

Companies in our directory listed in the same country and business area as Nexalis Therapeutics: Island Pharmaceuticals, Recce Pharmaceuticals, Biotron, Microba Life Sciences, Amplia Therapeutics, Biome Australia.

Investor discussion: Nexalis Therapeutics

Members talk about Nexalis Therapeutics (NX1). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open ASX:NX1 on TradingView.

Listing details

Nexalis Therapeutics Limited is a public biotech or pharmaceutical company listed on ASX under the ticker NX1, recorded under Australia. The directory classifies it as Clinical-stage biopharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Nexalis Therapeutics Limited
Ticker
NX1
Listing
ASX
Country or territory
Australia
Business scope
Clinical-stage biopharmaceuticals
ISIN
AU0000456733
Last quote in directory
2026-10-13
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.